Efficacy of 0.2 % Digluconate Chlorhexidine Mouthwash for Preventing Alveolar Osteitis After Third Molar Extraction
Launched by PIERRE FABRE MEDICAMENT · Mar 6, 2015
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female over 18 years old
- • Subject needing to undergo extraction of one impacted mandibular third molar
- • For woman of childbearing potential and woman in post menopausal period under hormonal substitution treatment, she must accept to plan the extraction of the impacted mandibular third molar only during the last week of the menstrual cycle.
- • Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation)
- Exclusion Criteria:
- • Existence or history of parotid gland disorders
- • Acute or history of recent acute pericoronitis at any tooth
- • Extraction of more than 1 third molar in the same surgical procedure
- • Subject at high risk of bacterial endocarditis (prosthetic heart valve, history of bacterial endocarditis, congenital cyanogenic heart disease)
- • Coagulation or haemostatic disorder or use of anticoagulants
- • Hypersensitivity to chlorhexidine or any of the excipients;
- • Hypersensitivity to any anesthetic agent;
- • Hypersensitivity to corticosteroids, analgesics including opioid drugs used for post-surgery pain relief
- • Intake of systemic vasodilator or vasoconstrictor
- • Intake of systemic or local (in the mouth) antibiotics within 7 days before Day 1 and/or any pre- or post-operative antibiotic prophylaxis planned to be prescribed during the study;
- • Use of any antiseptic mouthwash within 7 days before Day -1
- • Regular heavy smokers (more than 20 cigarettes per day)
- • Is pregnant or in post-partum period or a nursing mother
About Pierre Fabre Medicament
Pierre Fabre Medicament is a global pharmaceutical company dedicated to improving patient health through innovative therapies and high-quality healthcare solutions. With a strong emphasis on research and development, Pierre Fabre focuses on oncology, dermatology, and consumer health, striving to address unmet medical needs and enhance patient outcomes. The company is committed to ethical practices in clinical trial sponsorship, ensuring rigorous adherence to regulatory standards while fostering collaboration with healthcare professionals and stakeholders. Through its dedication to scientific excellence and patient-centric approaches, Pierre Fabre Medicament plays a vital role in advancing medical knowledge and therapeutic options worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Strasbourg, , France
Brest, , France
Metz, , France
Lyon, , France
Pierre Benite, , France
Toulouse, , France
Vilnius, , Lithuania
Riga, , Latvia
Kaunas, , Lithuania
Bordeaux, , France
Tallinn, , Estonia
Klaipeda, , Lithuania
Dijon, , France
Valmiera, , Latvia
Liepaja, , Latvia
Petit Quevilly, , France
Saint Maixent L'ecole, , France
Dauga Vpils, , Latvia
Patients applied
Trial Officials
Françoise TONNER
Study Director
Pierre Fabre Medicament
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials